Gilead Sciences, Inc. $GILD Shares Bought by &PARTNERS

&PARTNERS boosted its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 16.3% in the fourth quarter, according to the company in its most recent filing with the SEC. The firm owned 352,784 shares of the biopharmaceutical company’s stock after acquiring an additional 49,405 shares during the quarter. &PARTNERS’s holdings in Gilead Sciences were worth $43,309,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in GILD. Paulson Wealth Management Inc. raised its position in Gilead Sciences by 1.8% during the fourth quarter. Paulson Wealth Management Inc. now owns 3,887 shares of the biopharmaceutical company’s stock valued at $477,000 after acquiring an additional 67 shares in the last quarter. Essex Financial Services Inc. increased its holdings in shares of Gilead Sciences by 0.9% during the 4th quarter. Essex Financial Services Inc. now owns 7,724 shares of the biopharmaceutical company’s stock valued at $948,000 after purchasing an additional 71 shares in the last quarter. Alpha Cubed Investments LLC lifted its stake in shares of Gilead Sciences by 1.1% in the 4th quarter. Alpha Cubed Investments LLC now owns 6,619 shares of the biopharmaceutical company’s stock valued at $812,000 after purchasing an additional 75 shares during the period. Personal CFO Solutions LLC increased its holdings in Gilead Sciences by 1.7% in the fourth quarter. Personal CFO Solutions LLC now owns 4,572 shares of the biopharmaceutical company’s stock valued at $561,000 after buying an additional 76 shares in the last quarter. Finally, Moss Adams Wealth Advisors LLC raised its position in shares of Gilead Sciences by 1.7% in the fourth quarter. Moss Adams Wealth Advisors LLC now owns 4,446 shares of the biopharmaceutical company’s stock worth $546,000 after acquiring an additional 76 shares during the period. Institutional investors and hedge funds own 83.67% of the company’s stock.

Insider Transactions at Gilead Sciences

In other Gilead Sciences news, CEO Daniel Patrick O’day sold 15,000 shares of the stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $131.46, for a total value of $1,971,900.00. Following the completion of the sale, the chief executive officer owned 617,567 shares in the company, valued at approximately $81,185,357.82. This represents a 2.37% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Andrew D. Dickinson sold 3,000 shares of the company’s stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $125.40, for a total value of $376,200.00. Following the completion of the sale, the chief financial officer owned 171,646 shares of the company’s stock, valued at $21,524,408.40. This trade represents a 1.72% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 68,000 shares of company stock valued at $8,930,150 over the last 90 days. 0.30% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on the company. Morgan Stanley dropped their target price on Gilead Sciences from $175.00 to $168.00 in a research report on Friday, May 8th. Jefferies Financial Group began coverage on Gilead Sciences in a research report on Tuesday, March 10th. They set a “buy” rating and a $180.00 price target on the stock. Rothschild & Co Redburn dropped their price objective on Gilead Sciences from $170.00 to $167.00 in a report on Monday, May 11th. Truist Financial reissued a “buy” rating and issued a $157.00 price objective (up from $155.00) on shares of Gilead Sciences in a report on Friday, May 8th. Finally, Citigroup upped their target price on Gilead Sciences from $156.00 to $165.00 and gave the stock a “buy” rating in a research note on Monday, April 13th. Twenty-five analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $158.41.

Key Gilead Sciences News

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: The FDA accepted Gilead’s application for once-weekly oral Yeztugo (lenacapavir) for HIV prevention, advancing a potential new long-acting PrEP option and opening a possible new growth driver for the company. FDA Accepts Gilead’s Filing for Weekly Oral Yeztugo for HIV Prevention
• Positive Sentiment: Cantor Fitzgerald reaffirmed its Overweight rating and set a $155 price target, signaling continued analyst confidence in upside from current levels. Benzinga report on Cantor Fitzgerald rating
• Neutral Sentiment: Two Gilead insiders, including CFO Andrew D. Dickinson and Johanna Mercier, sold shares under pre-arranged 10b5-1 plans. The sales were disclosed normally and do not appear to signal an abrupt change in outlook, but they can still weigh on sentiment. SEC filing for Andrew D. Dickinson sale SEC filing for Johanna Mercier sale
• Neutral Sentiment: Recent reports noted GILD had previously dipped modestly in the prior session, but the stock’s latest move appears tied more to the FDA milestone and analyst support than to broader market action. Gilead Sciences (GILD) Stock Falls Amid Market Uptick: What Investors Need to Know

Gilead Sciences Trading Up 2.4%

Shares of Gilead Sciences stock opened at $127.23 on Wednesday. The company has a current ratio of 1.97, a quick ratio of 1.77 and a debt-to-equity ratio of 0.89. Gilead Sciences, Inc. has a twelve month low of $104.46 and a twelve month high of $157.29. The firm has a market capitalization of $157.96 billion, a PE ratio of 17.33 and a beta of 0.31. The firm’s 50-day moving average price is $132.61 and its 200 day moving average price is $134.32.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported $2.03 EPS for the quarter, topping the consensus estimate of $1.91 by $0.12. The company had revenue of $6.96 billion during the quarter, compared to analyst estimates of $6.91 billion. Gilead Sciences had a return on equity of 48.19% and a net margin of 30.99%.Gilead Sciences’s quarterly revenue was up 4.4% on a year-over-year basis. During the same period in the previous year, the business earned $1.81 EPS. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. On average, sell-side analysts predict that Gilead Sciences, Inc. will post -0.8 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, June 29th. Shareholders of record on Monday, June 15th will be paid a dividend of $0.82 per share. This represents a $3.28 annualized dividend and a yield of 2.6%. The ex-dividend date of this dividend is Monday, June 15th. Gilead Sciences’s payout ratio is 44.69%.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.